The content on this site is intended for healthcare professionals only
Dr Marwan Fakih speaks to ecancer in an online interview for the ESMO 2021 meeting about the CodeBreak 101 study.
He gives the background of the phase Ib study and explains that it aims to evaluate the combination of sotorasib, a KRASG12C inhibitor, and panitumumab, an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer.
Dr Fakih reports that results suggest that this combination was safe and tolerable, with adverse events consistent with what they expected. He concludes by discussing what they hope to discover when the data matures.
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC
The parotid gland; an unusual site of colorectal cancer metastasis
Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
